Viridian Therapeutics, Inc.\DE (VRDN) EBIT (2016 - 2025)
Historic EBIT for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to -$40.0 million.
- Viridian Therapeutics, Inc.\DE's EBIT rose 5206.88% to -$40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$328.1 million, marking a year-over-year decrease of 1592.56%. This contributed to the annual value of -$299.0 million for FY2024, which is 1752.21% down from last year.
- Latest data reveals that Viridian Therapeutics, Inc.\DE reported EBIT of -$40.0 million as of Q3 2025, which was up 5206.88% from -$106.8 million recorded in Q2 2025.
- Viridian Therapeutics, Inc.\DE's EBIT's 5-year high stood at -$14.1 million during Q3 2021, with a 5-year trough of -$106.8 million in Q2 2025.
- Its 5-year average for EBIT is -$53.1 million, with a median of -$51.2 million in 2023.
- Examining YoY changes over the last 5 years, Viridian Therapeutics, Inc.\DE's EBIT showed a top increase of 6790.11% in 2021 and a maximum decrease of 18236.59% in 2021.
- Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's EBIT stood at -$29.1 million in 2021, then crashed by 68.72% to -$49.1 million in 2022, then plummeted by 45.68% to -$71.5 million in 2023, then decreased by 22.38% to -$87.5 million in 2024, then skyrocketed by 54.26% to -$40.0 million in 2025.
- Its EBIT was -$40.0 million in Q3 2025, compared to -$106.8 million in Q2 2025 and -$93.9 million in Q1 2025.